Want to join the conversation?
Biopharmaceutical company $GILD said that its Marketing Authorization Application (MAA) for tenofovir alafenamide (TAF) 25mg has been fully validated and is under assessment by the European Medicines Agency (EMA). This drug is an investigational, once-daily treatment for adults with chronic hepatitis B virus infection, an inflammation of the liver.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th